Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The associational pathway of emotional exhaustion among college students under perception of involution: the mediation model of self-compassion and psychological resilience.

Frontiers in psychology·2026
Same author

Targeted Photodegradation of Misfolded Proteins via Self-photosensitizing with Molecularly Produced Light.

bioRxiv : the preprint server for biology·2026
Same author

Baicalein mitigates anti-tuberculosis-induced liver injury via inhibition of lipid peroxidation mediated by ferritinophagy and ferroptosis: Involvement of Yap 1/NCOA4 signaling.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment.

Journal of evidence-based medicine·2026
Same author

The EnvZ/OmpR two-component regulatory system regulates biofilm formation in <i>Salmonella pullorum</i> via interaction with the LuxS/AI-2 quorum sensing system and activation of the SoxR-AcrAB-TolC pathway.

Frontiers in microbiology·2026
Same author

A High-Affinity NIR Fluorescent Probe for Aβ Oligomers Enables Theranostics Through Disrupting Membrane Interaction and Aggregation.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: May 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K

Visualizable, AKR1C3-Activated Small-Molecule Antitumor Drug Conjugates with Ultra-Low Systemic Toxicity.

Ningfang Kang1, Shuainan Liu1, Xiaoyu Li1

  • 1School of Engineering, China Pharmaceutical University, Nanjing 210009, China.

Journal of Medicinal Chemistry
|May 2, 2026
PubMed
Summary

Researchers developed novel Exatecan conjugates (EP-1, EP-2) that selectively target tumors expressing the enzyme Aldo-keto Reductase Family 1 Member C3 (AKR1C3). These targeted agents show potent anticancer activity with significantly reduced systemic toxicity, offering a safer tumor therapy.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.7K

Related Experiment Videos

Last Updated: May 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.7K

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Developing targeted antitumor agents with minimal systemic toxicity is a significant challenge in cancer therapy.
  • Exatecan, a potent camptothecin derivative, has limitations in clinical use due to toxicity and efficacy issues.
  • Targeting tumor-specific enzymes like Aldo-keto Reductase Family 1 Member C3 (AKR1C3) offers a strategy for selective drug activation.

Purpose of the Study:

  • To design and synthesize novel Exatecan conjugates (EP-1 and EP-2) that are responsive to the tumor-enriched enzyme AKR1C3.
  • To evaluate the targeted drug release, cytotoxicity, and systemic toxicity of these novel conjugates.
  • To establish a biomarker-driven approach for developing safer and more effective antitumor therapies.

Main Methods:

  • Design and synthesis of two AKR1C3-responsive Exatecan conjugates (EP-1, EP-2) incorporating a fluorescence-quenched module.
  • In vitro cytotoxicity assays in cancer cells with varying AKR1C3 expression levels.
  • In vivo studies using a mouse model and zebrafish imaging to assess drug release and efficacy.

Main Results:

  • EP-1 and EP-2 demonstrated potent cytotoxicity in AKR1C3-high cancer cells, comparable to Exatecan.
  • The conjugates exhibited markedly reduced toxicity in AKR1C3-low and normal cells, indicating targeted activation.
  • EP-2 showed potent antitumor efficacy with significantly reduced systemic toxicity in a mouse model, surpassing Exatecan's safety profile.

Conclusions:

  • The novel AKR1C3-responsive Exatecan conjugates, particularly EP-2, are promising candidates for selective and safe tumor therapy.
  • This study presents a new paradigm for biomarker-driven antitumor drug design, enabling targeted drug delivery and activation.
  • The developed conjugates offer a potential solution to overcome limitations of existing chemotherapies and improve patient outcomes.